Invetso Quality Score — UTMD

Utah Medical Products, Inc. · 7.4/10 — Strong · Updated August 2026

7.4Strong

Last updated: August 2026

Factor Snapshot

Durability🟡 Moderate
Capital Efficiency🟡 Moderate
Growth Quality🟡 Moderate
Risk Profile🟢 Strong
Capital Allocation🟢 Strong
Scalability🟡 Moderate

Invetso Quality Score

🟢 7.4 (Strong)

Core Drivers

Exceptional balance-sheet resilience: UTMD’s near-debt-free structure and very high liquidity materially reduce financial downside and give it more operating flexibility than most global medtech peers.

Stable niche positioning with recurring demand: The business benefits from specialized medical-device demand, repeat consumables, and enough switching friction to support durable cash generation without relying on aggressive growth.

Disciplined stewardship and capital returns: Management has consistently favored conservatism, preserving optionality and supporting shareholder returns while avoiding the leverage and execution risk that weaken many smaller peers.

Key Constraints

Moat is real but not dominant: UTMD has niche protection, but it lacks the stronger structural advantages seen in top-tier medtech franchises, especially network effects, broad ecosystem lock-in, or category-defining scale.

Growth and capital efficiency are only moderate: The company looks more like a steady cash generator than a high-compounding platform, with modest ROIC and limited evidence of a faster growth runway.

Working-capital drag limits peer-relative upside: Long inventory cycles and a stretched cash conversion profile reduce redeployment speed and keep the company from translating its balance-sheet strength into stronger operating leverage.

Synthesis

UTMD stands out as a high-quality, low-risk niche medtech business, but not as a dominant compounder. The most important feature is the combination of durable cash generation and an exceptionally conservative balance sheet, which creates a favorable downside profile relative to global peers. That strength is tempered by a moat that is credible but not commanding, so the company’s long-term outcome depends more on steady execution than on structural share capture. Growth quality is adequate rather than exciting, and capital efficiency is solid but not elite, which keeps the profile from reaching the top tier. Relative to peers, UTMD is clearly above average on resilience and governance, but only moderate on scalability and compounding power. The result is a business that looks dependable and defensible, with upside driven by consistency rather than acceleration.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Utah Medical Products, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →